Abstract
Total androgen blockade, which consists of the inhibition of action of all androgens, has been described (1). On the basis of an open clinical trial, it was claimed that total androgen blockade gives much better results than simple testicular androgen ablation in metastatic prostate cancer and that it represents the only acceptable form of treatment of that disease (2). In order to test this claim, which is not supported by all investigators (3), a double-blind, randomized study comparing these two modes of treatment was initiated. Testicular androgen suppression is usually obtained by the administration of estrogens or LHRH agonists, or by orchiectomy. We feel that this last method is the safest, the simplest and the most reliable. It is independent of patient compliance and has no unexpected side effects or serious complications. It also avoids the possible flare which may have a deleterious effect (4–6). The suppression of action of other androgens at the level of the prostatic cell is obtained by administration of an antiandrogen (7–9).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Geller, J. and Albert J. The case for total androgen blockade in the management of metastatic prostate cancer, in: “The Management of Prostate Cancer,” D.S. Coffey, M. Resnick, A. Dorr and J. Karr (eds.), Plenum Publishing Corporation, New York (in press).
Labrie, F., Dupont, A. and Belanger, A. Complete androgen blockade for the treatment of prostate cancer, in “Important Advances in Oncology 1985”, V.T. De Vita, S. Hellman and S.A. Rosenberg, eds., Lippincott, Philadelphia, 1985.
Schulze, H., Oesterling, J.E., Isaacs, J. and Coffey D. Hormonal therapy of prostate cancer: limitations in the total androgen ablation concept, in: “The Management of Prostate Cancer”, D.S. Coffey, M. Resnick, A. Dorr and J. Karr (eds.), Plenum Publishing Corporation, New York (in press).
Santen, R.J., Warner, B., Demers, L.M., Dufau, M. and Smith J. Use of GnRH hormone agonists analogs, in “LHRH and its Analogs - A New Clas’s of Contraceptive and Therapeutic Agents”, B. Vickery, J.J. Nestor and E.S.E. Hafez, eds., MTP Press, Boston, 1984.
Trachtenberg, J. The treatment of metastatic prostatic cancer with a potent luteinizing hormone - releasing hormone analogue. J. Urol. 129:1149–1152, 1983.
The Leuprolide Study Group Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl. J. Med. pp. 1281- 1286, 1984.
Neumann, F. and Schenck, B. New antiandrogens and their mode of action. J. Reprod. Fértil. 24:129–145, 1976.
Irwin, R.J. and Prout, Jr., G.J. A new antiprostatic agent for treatment of prostate carcinoma. Surg. Forum 24:536–538, 1973.
Raynaud, J.P., Bonne, C., Bouton, M.M., Lagace, L. and Labrie, F. Action of a nonsteroidal antiandrogen RU 23908 in peripheral and central tissues. J. Steroid Biochem. 11:93–99, 1979.
Moguilewsky, Fiet, J., Tournemine C. and Raynaud, J.P. Pharmacology of an antiandrogen, Anandron, used as an adjuvant therapy in the treatment of prostate cancer. J. Steroid Biochem. 24:139–146, 1986.
Burton, S., and Trachtenberg, J. Effectiveness of antiandrogens in the rat. J. Urol. 136:932–935, 1986.
Beland, G., Elhilali, M., Fradet, Y., Laroche, B., Ramsey, E.W., Venner, P.M., and Tewari, H.D. Total androgen blockade versus orchiectomy in Stage D2 prostate cancer, in: “Progress in Clinical and Biological Research”, 243A:391–400, 1987.
Labrie, F., Dupont, A., Belanger, A., Poyet, P., Giguere, M., Lacoursiere, Y., Emond, J., Monfette, G. and Borsayi, J.P. Combined treatment with flutamide and surgical or medical(LHRH agonist) castration in metastatic prostatic cancer. The Lancet 4:48–49, 1986.
Emrich, L.J., Priore, R.L. and investigators of the NPCP. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 45:5173–5179, 1985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Beland, G. (1988). Comparison of Total Androgen Blockade and Orchiectomy in Metastatic Cancer of Prostate. In: Coffey, D.S., Resnick, M.I., Dorr, F.A., Karr, J.P. (eds) A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1667-1_22
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1667-1_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8925-8
Online ISBN: 978-1-4613-1667-1
eBook Packages: Springer Book Archive